TC19LGH: Tocilizumab in COVID-19 Lahore General Hospital
Study Details
Study Description
Brief Summary
The most accepted description of severe COVID-19 disease is development and over production of pro-inflammatory cytokines. Autopsy studies have been done on COVID-19 patients proved that severe disease is resulted due to deviant host-immune response and cytokine storm. Elevated inflammatory biomarkers like C-Reactive protein (CRP) and pro-inflammatory cytokines shown to be higher in severe disease of COVID-19. Several studies on severe COVID-19 have revealed raised levels of plasma cytokines like IL-6, IL-2, IL-10, Gamma interferon (INF), Tumor necrosis factor Alpha TNF. The Cytokines release syndrome (CRS) is a hyperinflammatory deadly syndrome characterized by release of uncontrolled immune system activation which is responsible for multi-organ failure. It has the main role in ARDS due to SARS-CoV-2 virus which binds to alveolar epithelium and resulting in IL-6 release that is responsible for increase alveolar-epithelium permeability. In many studies it has been observed that IL-6 have played a main role in CRS induction. Previous experiences from hyperinflammatory and cytokine storm syndromes recommends that early involvement of inhibiting CRS is essential to prevent lethal tissue damage and poor clinical outcome. In this scenario the judgement of clinical specialist who are suggesting that evidence of CRS can be cured with glucocorticoids, I/V immunoglobulin and anti-cytokine therapy cannot be ignored.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This is intervention single-center study, that will be done at Lahore General Hospital in which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed consent will be obtained from all patients who will agree to publish their data in this research. Patient's privacy and obey will be protected with the Helsinki Declaration.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group intervene with Tocilizumab Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection. Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers. |
Drug: Tocilizumab
4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.
Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Clinical response after administration [10 days]
Clinical improvement of COVID-19 patients by Tocillzumab The number of intubated patients. The number of patients with death.
Secondary Outcome Measures
- Clinical response to treatment [15 days]
Overall survival of COVID-19 patients after drug administration.
- Duration of hospitalization [15 days]
Number of days of hospital admission either in ICU or HDUs till date of discharge
- Clinical outcome of the treatment [15 days]
Mortality rate
- Supplemental Oxygen Requirement from Baseline [15 days]
Duration of increased supplemental oxygen requirement from baseline
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients of all ages, males and non-pregnant females who will be diagnosed COVID-19 positive by RT-PCR.
-
Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT chest.
-
Patient >55 years of age Or Age <55 with comorbid condition who will be unable to maintain O2 sat > 93% with 5-7 liter of oxygen.
-
Or Patient < 55 with no comorbid conditions, who will be unable to maintain O2 sat > 93% with 7-10 liter of oxygen.
-
Respiratory rate > 30-35/ min and >50% of radiological involvement of lung with typical lesions.
-
Along with > 50% deranged ≥ 2 biochemical markers CRP > 50 mg/l, LDH > 1000U/L, D.Dimer > 1mg/l or 1000 ng/ml, Serum Ferritin > 1000 ng/ml or mcg/l will be included in clinical trial.
Exclusion Criteria:
-
Patient who will not require supplemental oxygen during hospital stay.
-
Patients on Invasive mechanical ventilation (IMV).
-
Patients with respiratory rate < 30/mins and whose laboratory findings will not be deranged > 50%.
-
Patients with improving radiological findings will be excluded.
-
Patients suffering from Active TB
-
Herpes zoster
-
Multiple sclerosis,
-
Allergic to tocilizumab
-
Presences of chronic renal failure > 4 stage, GFR < 30ml/min/1.73m2.
-
ALT/AST > 5 times than normal values.
-
Presences of neutropenia < 500/mm3.
-
Platelets count less than 50 ×103 /µl.
-
Complicated diverticulitis/ intestinal perforation.
-
Immune-suppressive anti- rejection therapy.
-
Pregnant women.
-
Previous MI/ IHD, IV heart failure.
-
Psychiatric patients.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lahore General Hospital | Lahore | Punjab | Pakistan | 54500 |
Sponsors and Collaborators
- Lahore General Hospital
Investigators
- Study Director: Sardar Al-Fareed Zafar, Post-Graduate Medical Institute, Lahore General Hospital, Lahore Pakistan
Study Documents (Full-Text)
None provided.More Information
Publications
- Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, De Benedetti F, Behrens EM, Cron RQ, Nigrovic PA. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.
- Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020 Jul;111:102452. doi: 10.1016/j.jaut.2020.102452. Epub 2020 Apr 10. Review.
- Radbel J, Narayanan N, Bhatt PJ. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. Chest. 2020 Jul;158(1):e15-e19. doi: 10.1016/j.chest.2020.04.024. Epub 2020 Apr 25.
- Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503-1516. doi: 10.1016/S0140-6736(13)61048-X. Epub 2013 Nov 27. Review. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.
- Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020 Aug 18;173(4):268-277. doi: 10.7326/M20-2003. Epub 2020 May 6.
- LGH001